GSK-1482160（Cat No.:I043962）is a potent and selective P2X7 receptor antagonist developed by GlaxoSmithKline for research in inflammation, pain, and neurodegenerative diseases. The P2X7 receptor, an ATP-gated ion channel, plays a critical role in immune cell activation, cytokine release, and inflammasome signaling. By blocking this receptor, GSK-1482160 reduces inflammatory responses and neuronal damage. It has demonstrated promise in preclinical models for conditions such as chronic pain, multiple sclerosis, and Alzheimer’s disease. GSK-1482160 is also used in mechanistic studies to better understand purinergic signaling pathways and their therapeutic potential.